microdosing glp 1 perimenopause GLP-1 for Perimenopause: Benefits & Risks One Year on a GLP-1

IGF-1 LR3 is a modified IGF-1 with an extended amino acid sequence that has 13 additional amino acids at the N-terminus and a substitution of arginine for glutamic acid at position 3

Provenance Proof Points are all third party verified and evidenced through supply chains

Study A matched participants 1:1 to receive either placebo or bremelanotide subcutaneously three times daily for 15 days (1.25 mg/1.00 mg/1.00 mg on day 1 and 2.5 mg/2.0 mg/2.0 mg on following days), and Study B assigned participants to receive either once-a-day (2.5 mg) or twice-a-day (2.5 mg/2.0 mg) doses of bremelanotide versus placebo for four days

The reaction was terminated by the addition of NEM to a final concentration of 50 mM

Herbal compounds do not replace pharmaceutical interventions requiring medical supervision and dose titration

Retatrutide can also cause dysesthesia (tingling, numbness) at higher doses